Clinical trial
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
NCT00045968 · Northwest Biotherapeutics, Industry · Unknown status
Key facts
| NCT number | NCT00045968 |
|---|---|
| Title | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer |
| Official title | A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) |
| Acronym | GBM |
| Lead sponsor | Northwest Biotherapeutics, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor |
| Intervention type | Drug |
| Interventions | Dendritic cell immunotherapy |
| Enrollment | 348 |
| Start date | Dec 1, 2006 |
| Primary completion | Nov 1, 2022 |
| First posted | Sep 19, 2002 |
| Last update posted | May 18, 2022 |
| Countries | Canada, Germany, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: